Advances in Cancer Biology - Metastasis Исследования рака
Advances in precision brain tumor care: From intelligent diagnostics to transformative therapies
Аннотация
Background/Objectives: Brain tumors are a heterogeneous category of neoplasma, which develops in the central nervous system. In the current review, we mainly refer to primary brain tumors, especially gliomas and glioblastoma, because these are the most prevalent malignancies in neuro-oncology and the primary target of most of the emerging precision diagnostic and therapeutic efforts. Even though neuro-oncology has advanced, there are still constraints in clinical outcomes related to early tumour detection, proper stratification, and treatment resistance. There is an increasing need to incorporate emerging diagnostic platforms and precision therapy innovations to enhance survival and long-term disease control. Methods: A literature review was conducted of multi-omics diagnostics, radiogenomics, artificial intelligence-based predictive models, innovative imaging approaches, targeted therapy, immuno-oncology, and nanotechnology-based drug delivery systems. Emphasis was placed on technologies with the established mechanistic understanding, increased diagnostic sensitivity, increased therapeutic selectivity, and excellent translatability. Results: New diagnostic modalities such as liquid biopsy, circulating tumor DNA profiling, single-cell sequencing, high-field MRI, advanced PET tracers, and AI-enhanced radiology have great potential to detect tumors earlier, classify them more accurately, and dynamically track their response to treatment. Several emerging therapeutic approaches, including CAR-T and CAR-NK cell therapies, checkpoint inhibitors, CRISPR-based genome editing, and nanotechnology-based delivery systems, are currently in early clinical or preclinical stages and are being investigated for their potential to overcome the blood-brain barrier, optimize tumor targeting, and mitigate therapeutic resistance. Moreover, digital pathology and computational models provide adequate resources for individualised treatment planning and immediate clinical decision support. Conclusions: In short, these new diagnostic and therapeutic frontiers indicate a paradigm shift in the management of brain tumours. However, many remain under clinical investigation and require prospective validation before routine clinical adoption. The combination of high-level imaging, computational intelligence, and tailored treatment options offers an avenue to improved diagnosis, personalised treatment plans, better survival rates, and, eventually, a new paradigm of care in precision neuro-oncology.